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Abstract
Cyclin-dependent kinases (Cdks) are principal drivers of cell division and are an
important therapeutic target to inhibit aberrant proliferation. Cdk enzymatic activity
is tightly controlled through Cyclin interactions, posttranslational modifications, and
binding of inhibitors such as the p27 tumor suppressor protein. Spy1/RINGO (Spy1)
proteins  bind  and  activate  Cdk  but  are  resistant  to  canonical  regulatory
mechanisms  that  establish  cell-cycle  checkpoints.  Cancer  cells  exploit  Spy1  to
stimulate proliferation through inappropriate activation of Cdks, yet the mechanism
is unknown.  We have determined crystal  structures of the Cdk2-Spy1 and p27-
Cdk2-Spy1  complexes  that  reveal  how  Spy1  activates  Cdk.  We  find  that  Spy1
confers structural changes to Cdk2 that obviate the requirement of Cdk activation
loop  phosphorylation.  Spy1 lacks  the  Cyclin-binding  site  that  mediates  p27 and
substrate  affinity,  explaining why Cdk-Spy1 is  poorly  inhibited by p27 and lacks
specificity for substrates with Cyclin-docking sites. We identify mutations in Spy1
that  ablate  its  ability  to  activate  Cdk2  and  to  proliferate  cells.  Our  structural
description of Spy1 provides important mechanistic insights that may be utilized for
targeting upregulated Spy1 in cancer.  
Introduction
Cyclin-dependent kinases (Cdks) are central cell-cycle regulatory enzymes that
control cell fate decisions through phosphorylation of numerous protein substrates
(Morgan, 2007). Cdks stimulate cell-cycle progression in normal and cancer cells
and are a promising therapeutic target for halting cell proliferation (O'Leary, Finn et
al.,  2016,  Stone,  Sutherland  et  al.,  2012).  Cdk  activity  is  regulated  by  several
mechanisms  that  are  critical  for  the  intrinsic  oscillations  of  the  cell  cycle  and
response  of  the  cell  cycle  to  external  inputs  such  as  growth  factor  signaling
(Morgan, 2007). Typically the Cdk catalytic domain remains inactive until bound by
the Cyclin subunit,  and other kinases phosphorylate Cdk to stimulate further its
enzymatic activity. Cdk activity can also be inhibited through the direct binding to
Cdk inhibitor proteins that either prevent Cdk-Cyclin assembly or form a ternary
repressed complex. Tumor cells acquire genetic changes that bypass Cdk inhibition
either by upregulating Cyclin levels or downregulating Cdk inhibitor levels  (Kim &
Sharpless, 2006, Malumbres & Barbacid,  2009, Sherr,  1996). In addition, several
viruses  have  co-opted  Cyclins  to  inappropriately  drive  host  cell  proliferation
(Swanton, Mann et al., 1997). 
Several  noncanonical  (i.e.  non-Cyclin)  protein  regulators  of  Cdk  activity  play
important roles in normal and cancer cell growth (Nebreda, 2006). Here we focus on
the structure and activity of the Cdk regulator known as Speedy (Spy1; also known
as RINGO) (Ferby, Blazquez et al., 1999, Lenormand, Dellinger et al., 1999, Porter,
Dellinger et al., 2002). There are five known mammalian Spy1 paralogs, which are
all highly expressed in the testes (Cheng, Xiong et al., 2005b, Dinarina, Perez et al.,
2005). Speedy A (Spy1A, herein referred to as Spy1) is the best characterized and
the only isoform that is ubiquitously expressed in somatic  tissues  (Porter  et al.,
2002). The physiological roles of Spy1 proteins are just beginning to be uncovered.
Spy1 is critical for meiosis in both egg and sperm (Cheng et al., 2005b, Ferby et al.,
1999,  Mikolcevic,  Isoda  et  al.,  2016,  Porter  et  al.,  2002).  Expression  of  non-
degradable  forms  of  Spy1  induces  unregulated  cell  proliferation  and  oncogenic
properties (Al Sorkhy, Craig et al., 2009), and Spy1 overexpression is implicated in
the initiation of tumorgenesis  (Cheng et al.,  2005b, Ferby et al.,  1999, Golipour,
Myers et al., 2008, Mikolcevic et al., 2016, Porter et al., 2002). 
Spy1 proteins share no significant sequence homology with Cyclins (Figure EV1).
All  Spy1 paralogs  contain  a highly-conserved domain of  about  130 amino acids
called  the  S/R  box  (Speedy/Ringo  box),  which  is  required  for  Cdk  binding  and
activation  (Cheng et al., 2005b, Dinarina et al., 2005). Spy1 can directly bind and
activate both Cdk1 and Cdk2, and Spy1 overexpression induces cells to progress
faster  through the cell  cycle  and to override checkpoints  (Barnes,  Porter  et  al.,
2003, Gastwirt, Slavin et al., 2006, McAndrew, Gastwirt et al., 2009). 
An important difference between Spy1 and classical Cyclin proteins is that Cdk-
Spy1 activity is refractory to the well-characterized mechanisms that regulate Cdk-
Cyclin  activity.  For  example,  unlike  Cdk-Cyclins,  Cdk-Spy1 does  not  require  the
positive input of Cdk-activating kinase (CAK) for activity, and Spy1-bound Cdk2 is
not inhibited by the Cdk inhibitors p21 or p27 (Al Sorkhy, Fifield et al., 2016, Cheng,
Gerry et  al.,  2005a,  Karaiskou,  Perez et al.,  2001).  Spy1 also confers  expanded
specificity to Cdk  (Cheng et al., 2005a), implying that Spy1-bound Cdk can target
noncanonical  Cdk  substrates.  Therefore,  Spy1  is  a  potent  Cdk  activator  whose
expression overrides normal cell-cycle signaling inputs that control  Cdk function.
Whether  there  is  reduced  access  of  Cdk  inhibitors  to  the  Cdk  active  site  and
whether  Spy1-bound  Cdks  assume  a  different  conformation  have  never  been
resolved. 
We have determined the first structures of Spy1 that explain how Spy1 activates
Cdk  to  stimulate  cell-cycle  progression.  We  find  that  despite  its  low  sequence
homology with Cyclin, Spy1 adopts a Cyclin fold that binds and induces an active
Cdk  conformation.  The  structure  and  biochemical  analysis  reveal  how  Spy1
coordinates the Cdk activation loop independent of CAK phosphorylation. We also
find that Spy1 lacks a binding site for p27 and substrates, which results in weak
Cdk-Spy1 inhibition and a lack of  preference for substrates containing canonical
Cyclin docking sites. Our work explains why cancer cells may upregulate Spy1 as a
Cdk activator that is refractory to protective cell-cycle checkpoint mechanisms. 
Results
Spy1 contains a Cyclin fold that binds Cdk2 and induces its active conformation
We grew crystals and solved the 2.7 Å structure of human Cdk2 bound to a
construct from human Spy1A (residues 61-213) corresponding to the S/R box25,26
(Table EV1 and Fig 1). Cdk2 and the S/R box form a stoichiometric heterodimer, and
there is one complex in the crystal asymmetric unit. Cdk2 has the bi-lobal structure
typical of protein kinases. The Cdk2 N-terminal domain contains a beta sheet and
the PSTAIRE activation helix (called C-helix in other kinases), while the C-terminal
domain is helical and contains the T-loop (activation loop). The structure of Cdk2 in
the complex is  similar  to  structures  of  Cdk2 bound by Cyclin A (CycA)  (Fig  1B)
(Jeffrey, Ruso et al., 1995, Russo, Jeffrey et al., 1996a, Russo, Jeffrey et al., 1996b).
The PSTAIRE helix is pushed in towards the center of the N-lobe with E51 pointing
towards the active site (Fig 1A). The T-loop contacts Spy1 and is pulled ~5-6 Å away
from the active site relative to its position in the structure of Cdk2 alone. These
PSTAIRE and T-loop conformations are associated with active kinase, which supports
and explains previous findings that Spy1 can substitute for a canonical Cyclin in
stimulating Cdk activity  (Cheng et al., 2005a, Karaiskou et al., 2001, Porter et al.,
2002). 
The S/R box structure, despite its low sequence homology with Cyclin proteins
(Fig EV1), has a Cyclin box fold (CBF), which consists of a five-helix bundle arranged
with four helices (1, 2, 5) surrounding a central helix (3) (Figs 1C and 1D)
(Noble, Endicott et al., 1997). The S/R box contains one additional helix N-terminal
to the CBF (1’) and two short helices C-terminal to the CBF (6 and 7). Unlike the
canonical Cdk-activating Cyclins, Spy1 contains only a single CBF. It binds Cdk2 in
the same position as the N-terminal CBF of Cyclin A (Jeffrey et al., 1995). Spy1 3,
5, the 3-4 loop, and the 5-6 loop contact the PSTAIRE helix in Cdk2, while the
Spy1 3-4 loop, 6, and the loop that follows 7 bind and position the Cdk2 T-loop.
The  most  extensive  interface  between  Spy1  and  Cdk2  occurs  between  the
PSTAIRE  helix  and helices  3 the  5 of  Spy1 (Figs  1C and 1D and Fig  2).  The
interface consists of several hydrogen bonds involving charged sidechains (Fig 2A).
For example, R164 and D165 in 5 of Spy1 hydrogen bond with backbone atoms in
the loop just N-terminal to the PSTAIRE helix, and the C-terminus of the PSTAIRE
helix is bound through hydrogen bonds involving R174 and D172 in Spy1. Cdk2 R50,
which is in the center of the PSTAIRE helix, makes a number of hydrogen bonds with
the C-terminus of the Spy1 3 helix and D136 in the 3-4 loop. The PSTAIRE-Spy1
interface is also stabilized by a group of hydrophobic residues in Cdk2 consisting of
V44, I49, and I52. Speedy inserts W168 and Y173 into this hydrophobic patch, and
the indole nitrogen of W168 also forms a hydrogen bond with S53 of Cdk2 (Fig 2A). 
The S/R box secondary structural elements at the PSTAIRE interface align with
CycA (Fig 1C), and several hydrogen bond contacts between the PSTAIRE helix and
Spy1 are similar to those present in the Cdk2-CycA structure (Jeffrey et al., 1995). In
contrast, the PSTAIRE hydrophobic patch is engaged differently by CycA. Whereas
Spy1 primarily uses W168, CycA uses F304 and L299. These differences exemplify
how the remarkably divergent sequences among Cdk activators still converge on
structures that induce the kinase into its active conformation. It is noteworthy that
many residues in Spy1 that contact the PSTAIRE helix are not strictly conserved
between the Spy1 paralogs (Fig 1D). For example, few residues in 5 and the 5-6
loop are conserved, and there are differences in the size of hydrophobic sidechains
at  several  positions  including  at  W168.  This  variation  within  the  Spy1  family
suggests that this interface is pliable and that the PSTAIRE helix is engaged and
positioned in subtly different ways. 
Spy1 binding induces an active Cdk T-loop conformation
It has previously been observed that human Xenopus Spy1/RINGO can increase
the extent of histone peptide phosphorylation by Cdk1 or Cdk2 and that this activity
does not depend on activity of the upstream Cdk activating kinase (CAK) (Cheng et
al., 2005a, Karaiskou et al., 2001). Our structure of Cdk2-Spy1 reveals that the Spy1
S/R-box contacts the T-loop and draws it away from the kinase domain (Fig 1C).
Cyclin binding pulls the T-loop out of the active site to some extent (Fig 1C) as
observed  in  comparing  the  structures  of  Cdk2-CycA  and  Cdk2  alone  (Debondt,
Rosenblatt et al.,  1993, Jeffrey et al.,  1995, Russo et al.,  1996b). However, until
T160 is phosphorylated, T160 and its adjacent residues still  partially occlude the
substrate-binding  site  (Fig  3A).  Insofar  that  it  is  completely  removed  from  the
substrate cleft, the unphosphorylated T-loop conformation in Cdk2 bound to Spy1
more closely resembles the conformation of the T-loop when Cdk2 is bound to CycA
and phosphorylated on T160 (Fig 3A). 
These  structural  data  support  the  hypothesis  that  Spy1  can  stimulate  Cdk
activity by inducing a completely active T-loop structure, and therefore Cdk2-Spy1
activity does not depend on whether T160 is phosphorylated by CAK. To further test
this  idea  and  quantitatively  measure  Cdk-Spy1  kinetics  towards  cell-cycle
substrates, we measured steady-state phosphorylation rates of Cdk2-Spy1 towards
protein fragments of FoxM1 (Fig 3B and 3C) and the retinoblastoma protein (Rb)
(Fig  EV2).  We  purified  recombinant  human  FoxM1B  (hereafter  called  FoxM1)
residues 526-748, which corresponds to a predicted disordered region of the protein
and contains 5 consensus Cdk sites that are important for FoxM1 activation and
mitotic gene expression (Laoukili, Alvarez et al., 2008, Major, Lepe et al., 2004). We
phosphorylated this  fragment with  32P-labeled ATP in reactions  containing Cdk2-
CycA, Cdk2-Spy1 (S/R box domain) and both kinase complexes phosphorylated by
CAK  (phosCdk2-CycA  and  phosCdk2-Spy1).  We  assayed  the  rate  of  phosphate
incorporation as a function of FoxM1 concentration by measuring SDS-PAGE band
intensity  after  phosphorimaging.  Consistent  with  previous  assays  using  other
substrates  (Cheng  et  al.,  2005a,  Karaiskou  et  al.,  2001),  we  find  that
phosphorylation of Cdk2-CycA leads to a 2-fold decrease in KM (Michaelis constant)
and  a  25-fold  increase  in  the  maximum  initial  rate  (Vmax).  In  contrast,  both
unphosphorylated and phosphorylated Cdk2-Spy1 have similar KM and Vmax values,
with the Vmax falling between unphosphorylated and phosphorylated Cdk2-CycA. We
found similar results phosphorylating the C-terminal domain of the retinoblastoma
protein (Fig EV2). 
The structural  details at the Cdk2-Spy1 interface explain how Spy1 is able to
induce the active T-loop conformation (Fig 4A). The interface is composed primarily
of hydrogen bond and 
electrostatic interactions. Several interactions are made by three consecutive acidic
residues (E134, E135, and D136) in the Spy1 3-4 loop, which inserts between the
Cdk2 PSTAIRE helix and T-loop.  Spy1 D136 coordinates three arginines in Cdk2,
including one from the PSTAIRE helix (R50) and one from the T-loop (R150). This
position of D136 is analogous to the position of the T160 sidechain phosphate in the
phosCdk2-CycA  structure  (Russo  et  al.,  1996b),  and  the  phosphate  similarly
coordinates the arginine triad. Although T160 is unphosphorylated in the Cdk2-Spy1
complex, Spy1 D136 also hydrogen bonds with the Cdk T160 peptide amine such
that the T160 location is identical to that of phosphorylated T160 in the phosCdk2-
CycA structure. Spy1 further pulls the T-loop out from the substrate cleft through
interactions with residues that are just N-terminal to T160. Spy1 E135 hydrogen
bonds with the sidechain oxygen and peptide amide of Cdk2 T158, and Spy1 D97
forms a salt bridge with Cdk R157. Both of these interactions have no analogy in the
Cdk2-CycA structures. In contrast to the Spy1 residues that contact the PSTAIRE
helix,  the Spy1 residues that bind the T-loop are highly conserved among Spy1
paralogs  (Fig  1C).  This  strict  conservation  suggests  that  that  proper  T-loop
positioning is a critical aspect of Spy1-induced activation of Cdk. 
Mutation of T-loop-binding residues inactivate Spy1
We tested using the phosphorylation assay the prediction from the structure that
the  interactions  made  by  D97  and  E135  with  the  T-loop  are  critical  for  Cdk2
activation  by  Spy1.  We  expressed  and  purified  a  full  length  D97N/E135Q Spy1
mutant (Spy1-DE) and found that it showed no activity towards FoxM1 (Fig 4B) or
Rb  (Fig  EV2).  Previous  data  support  that  the  proliferative  effects  of  Spy1  are
dependent on activation of Cdk2 (Porter et al., 2002). Using cell lines and conditions
previously used to study this Spy1 activity, we tested if the Spy1-DE mutant would
retain the proliferative capabilities of Spy1-wildtype. Spy1-DE or wild-type plasmids
were expressed in HEK 293 and NIH 3T3 cells and cell proliferation monitored over 5
days (Fig 4C). Mutation of D97 and E135 in the T-loop of the DE-mutant abrogated
the ability of Spy1 to proliferate cells. 
Spy1 lacks the canonical Cyclin binding cleft for protein inhibitors 
In  addition  to  activating  Cdk  through  structural  reorganization  of  the  kinase
domain,  Cyclin  proteins  regulate  Cdk  activity  through  binding  substrates  and
members of the Kip family of protein inhibitors including p27 (Brown, Noble et al.,
1999,  Russo  et  al.,  1996a,  Schulman,  Lindstrom et  al.,  1998,  Sherr  &  Roberts,
1995). Kip proteins and substrates use a (K/R)xLF or (K/R)xLxF sequence motif that
docks into a cleft formed between helices 1 and 3 of  the Cyclin N-terminal CBF
(Brown et al., 1999, Russo et al., 1996a). The cleft is called the MRAIL site, because
of the Cyclin sequence in 1 at the site. Notably, the MRAIL sequence is missing in
Spy1, and the docking cleft is not present in the Cdk2-Spy1 structure (Fig 5A). The
1 and 3 helices are shorter in Spy1 and lack pockets for binding the consensus
leucine  or  phenylalnine  in  the  Kip/substrate  motif  (e.g.  L32  and  F33  in  p27).
Moreover, the interactions between the 1 and 3 helices position sidechains (such
as L82 and W147) to occlude the p27 docking surface.
While Spy1 association with p27 has been detected in cells,  Spy1 expression
overcomes a p27 induced cell arrest, and Spy1 induces Cdk2 activity in lysates in
the presence of p27 (Al Sorkhy et al., 2016, McAndrew, Gastwirt et al., 2007, Porter,
Kong-Beltran  et  al.,  2003).  Our  structural  data  demonstrate  that  Spy1 lacks  an
intact p27-binding site and suggest that p27 poorly inhibits Cdk2-Spy1 activity. To
test this hypothesis, we performed the 32P labeling reaction using FoxM1 substrate
in the presence of increasing concentrations of the kinase inhibitory domain of p27
(p27KID) (Fig 5B). p27KID potently inhibits Cdk2-CycA with a K i ~10 nM. In contrast,
p27KID shows little inhibition of Cdk2-Spy1 (full-length Spy1) even at concentrations
~ 1 M, and our measurements fit a Ki ~ 5 M. 
Considering that Spy1 lacks the MRAIL binding cleft and that Cdk2 has been
found in complexes with p27 and Spy1 in cells,  we hypothesized that the Cdk2
mediates  the  p27-Spy1  association  within  the  ternary  complex.  We  found  by
isothermal titration calorimetry that p27KID binds Cdk-Spy1 (Kd = 180  70 nM) (Fig
EV3). This affinity is similar to that previously reported for Cdk2 alone and lower
than  the  affinity  for  Cdk2-CycA  (Kd ~  4  nM)  (Lacy,  Filippov  et  al.,  2004).  We
crystallized  the  p27-Cdk2-Spy1  complex  and  determined  its  structure  to  3.5  Å
(Table EV1 and Fig 5C). The structure of Spy1 in the ternary complex overlays well
with its structure in the binary complex (RMSD = 0.436 Å). Electron density is only
observable  for  p27  residues  51-91,  which  corresponds  to  the  region  that  binds
Cdk2. The structure of p27 in this region is similar to the structure of p27 bound to
Cdk2-CycA (Russo et al., 1996a). Although present in the crystallization construct,
the part of p27 that binds CycA in the ternary p27-Cdk2-CycA complex is not visible,
which is consistent with the lack of a p27 binding site in the S/R box of Spy1. The
structure of Cdk2 in the ternary complex with Spy1 overlays well with its structure
in the ternary complex with CycA. The changes to the Cdk2 N-terminal lobe and
insertion of p27 residues into the ATP binding site are consistent with an inactive
kinase.
From these observations, we conclude that p27 binds the Cdk2-Spy1 complex
weakly  due  to  the  lack  of  the  MRAIL  site,  but  when  bound,  p27  is  capable  of
inhibiting Cdk2 as in the Cdk2-CycA-p27 complex. However, it is notable that our
measured Ki of the p27KID domain is ~25-fold weaker than the Kd that we measured
for its association. We suggest that the bridging interaction p27 makes with both
the kinase and Cyclin domains may play an additional role in inhibition, perhaps by
restricting dynamics that are necessary for catalysis.
Substrate  phosphorylation  by  Cdk2-Spy1  is  not  enhanced  by  Cyclin-docking
sequences 
We  also  tested  whether  Cdk2-Spy1  was  insensitive  to  the  presence  of  the
(R/K)xLxF motif in a substrate (Fig 6). We phosphorylated an Rb C-terminal domain
construct (Rb771-928,  called RbC), which contains seven phosphorylation sites. RbC
includes  a  KxLxF  sequence  that  has  been  shown  to  be  critical  for  Rb
phosphorylation by Cdk-Cyclin complexes  in  vitro and in cells  (Adams,  Li  et  al.,
1999, Hirschi, Cecchini et al., 2010). We compared Cdk2-CycA and Cdk2-Spy1 (full
length Spy1) in  their  ability  to  phosphorylate  RbC and a mutant (F877A) in the
KxLxF motif. In the steady-state kinetic assay with Cdk2-CycA, we find that Vmax/KM is
7-fold higher for RbC wild-type than it is for RbC containing the F877A mutation. In
contrast, in the reactions with Cdk2-Spy1, the Vmax/KM is similar for the substrates
containing  the  wild-type  and  mutant  docking  site.  These  data  indicate  that
substrate capture by Cdk2-CycA is more sensitive to the presence of the KxLxF site.
Discussion
Comparison of Spy1 and other Cyclin-like proteins 
The  Cdk2-Spy1  structure  reveals  that  the  Cdk  interaction  surface  of  Spy1
resembles that of Cyclin, particularly in the arrangement of the CBF helices (3 and
5) that position the PSTAIRE helix in its active conformation (Fig 1B). While the
primary sequence is  not  strictly  conserved,  the chemical  nature of  the residues
responsible for Cdk interaction in this region is conserved. The remainder of the S/R
box does not overlay well with Cyclins, and there are important differences in how
the Cdk T-loop is bound. These facts suggest that Speedy and Cyclins did not evolve
from a common gene, but their evolution converged on a structure that activates
Cdk. The active conformation of Cdk2 in the structure is consistent with our data
confirming that S/R box-Cdk2 has activity and previous data that Xenopus S/R box
alone is able to activate Cdk2  (Cheng et al., 2005a, Dinarina et al., 2005). It has
been reported that the S/R box domain from mouse SpyA is not sufficient for Cdk2
activation (Cheng et al., 2005b), however based on the domain boundaries in that
study, we suggest that the expressed construct may have been too truncated and
not stable.  
Several  examples  of  non-Cyclin  proteins  have  been  reported  to  positively
regulate Cdk. For example, in neuronal cells, the protein p35 binds and activates
Cdk5 (Dhavan & Tsai, 2001, Tarricone et al., 2001), and the protein Cks binds Cdk1
and  Cdk2  to  stimulate  activity  towards  cell-cycle  substrates  phosphorylated  at
multiple  sites  (Koivomagi  et  al.,  2013,  McGrath  et  al.,  2013,  Pines,  1996).  In
organizing the active conformation of Cdk using a single CBF,  Spy1 bares some
similarities to how the neuron specific noncanonical Cdk-activator p35 binds Cdk5
and how the budding yeast activator Pho80 activates the Pho85 kinase (Huang et
al., 2007, Tarricone et al., 2001). p35 binds and activates Cdk5 without the need for
T-loop phosphorylation, and the T-loop conformations are similar in the Cdk2-Spy1
and Cdk5-p35 structures (Tarricone et al., 2001). However, the details of the Spy1-
T-loop  and  p35-T-loop  interactions  are  quite  distinct,  and  there  is  overall  poor
conservation between Spy1 and p35 (Fig EV1).
Mechanism for Spy1-mediated Cdk2 activation
Our structure offers a clear explanation for why Cdk2 does not require T-loop
phosphorylation for activity when bound by Spy1. Spy1 utilizes a set of conserved
charged residues to bind the T-loop and pull it into its active conformation away
from the Cdk2 substrate-binding site. We find that mutation of two of these residues
(D97 and E135) results in loss of kinase activity and Spy1 function in driving cell
proliferation and overriding DNA damage induced checkpoints (Fig 4). We observe
no differences in the position of T14 and Y15 in the structure compared to the Cdk2-
CycA complex, which is consistent with a report that Cdk2-Spy1 responds like Cdk2-
CycA to inhibitory phosphorylation on these sites (Dinarina et al., 2005). Spy1 lacks
the MRAIL binding cleft, which is present in Cyclin and is accessed by protein Cdk
inhibitors and substrates. Accordingly, we find that unlike Cdk2-CycA, Cdk2-Spy1 is
not inhibited by p27 and does not show preference for substrates that contain RxLF-
type docking motifs. Previous reports have demonstrated direct binding between
Spy1 and p27 that depends on arginines within residues 170-180 of Spy1 (Al Sorkhy
et al., 2016, Porter et al., 2003). In contrast, our structural data indicate that there
is  no  direct  interaction  and  that  the  association  is  mediated  by  Cdk.  This
discrepancy  may  be  due  to  a  role  for  the  Spy1  C-terminal  region  that  resides
outside of the S/R box.
Our data are in agreement with previous reports that Cdk2-Spy1 activity towards
consensus  Cdk phosphorylation sites is  not as efficient  as  phosCdk2-CycA when
assaying purified proteins (Fig 3 and Fig EV2) (Cheng et al., 2005a, Dinarina et al.,
2005). Previous data demonstrate that while Cdk2-CycA prefers lysine or arginine at
the +3 position of the phosphorylation site ((S/R)PX(K/R), Cdk2-Spy1 tolerates most
amino  acid  substitutions  at  the  +3  position,  preferring  tyrosine,  arginine,  or
tryptophan (Cheng et al., 2005a). Considering that the active site structures of the
two  complexes  appear  nearly  identical,  it  is  not  clear  why  this  difference  is
observed, but it may be due to subtle differences in affinity.  We also note that the
weaker  Cdk2-Spy1  activity  compared  to  Cdk2-CycA  may  be  an  artifact  of  the
relative stabilities of the purified enzymes.  
Roles of Spy1 in development and oncogenesis
Our data provide strong support for the hypothesis that Spy1 activates Cdk in a
manner that is insensitive to many of the regulatory mechanisms that minimize Cdk
activity. This insensitivity is likely important in the context of development, during
which the cell cycle needs to progress in the presence of complex and potentially
conflicting growth signals, and therefore, this hypothesis fits with observations that
Spy1 is expressed in oocytes and the testes (Cheng et al., 2005b, Ferby et al., 1999,
Mikolcevic  et  al.,  2016,  Porter  et  al.,  2002) and  the  tight  regulation  in  several
developing tissues. The insensitivity of Spy1 to antiproliferative signals may push
stem cells  past  barriers  at  select  time points  during  development  as  has  been
proposed in the brain (Lubanska, Market-Velker et al., 2014). 
Spy1 was originally  isolated in  2  different  screens  designed to  identify  gene
products capable of overriding cell cycle checkpoints (Ferby et al., 1999, Lenormand
et al., 1999). Spy1 has been shown to override cell cycle checkpoints and apoptotic
signaling and promote cell proliferation following a host of different forms of DNA
damage  (Barnes et al., 2003, McAndrew et al., 2009, Mikolcevic et al., 2016). As
distinct hallmarks of cancer, this prompted the study of Spy1 in tumor initiation and
promotion  by  a  number  of  different  research  groups.  Spy1  levels  are  high  in
hepatocellular carcinoma, lymphoma, malignant glioma, ovarian cancer, and breast
cancer and knockdown of Spy1 protein significantly reduces tumorigenic capacity in
numerous systems  in vivo and  in vitro (Al Sorkhy et al.,  2012, Bisteau & Kaldis,
2014, Golipour et al., 2008, Hang et al., 2012, Ke et al., 2009, Lu et al., 2016, Zhang
et al., 2012 Lubanska et al., 2014). These data suggest the possibility that Spy1
targeting may be a novel anticancer therapy. To date, targeting Cdk activity using
Cdk inhibitors  has had some clinical  success  (O'Leary et al.,  2016,  Stone et al.,
2012),  however  the  roles  of  Cyclin-like  proteins  have  not  been  considered  and
information  on  how to  best  stratify  patient  populations  for  these  studies is  still
accumulating. Our structural resolution of how Cdk is activated by Spy1, particularly
the unique positioning of the Cdk T-loop, provides the foundation for developing
Cdk-Spy1 specific kinase inhibitors that may have utility in the clinic.
Materials and Methods
Protein expression and purification.
Wild-type human Spy1,  S/R  box  (residues  G61-D213),  or  CycA  were each
expressed as an MBP fusion protein from a codon-optimized sequence inserted into
the  pMBP  vector  in SoluBL21  E.  coli.  Wild-type  full-length  human  Cdk2  was
expressed separately as a GST fusion protein from a pGEX in vector in  E. coli. In
both cases, transformed cells were grown to an OD between 0.6 and 1, cooled in an
ice bath for 20 min, and expression was induced with 1mM IPTG overnight at 18°C.
Cell  pellets were resuspended in a wash buffer containing 25mM HEPES pH 7.5,
200mM  sodium  chloride,  1mM  DTT.  The  resuspended  cells  from  the  separate
batches of  E. coli were lysed together with 1mM PMSF to form the Cdk2-Spy1 (or
Cdk2-CycA) complex. The clarified lysate was purified with glutathione Sepharose
resin. The eluate from the glutathione Sepharose resin, which contained both Cdk2
and Spy1, was then bound to amylose resin and washed with the lysis buffer. The
tags were then cleaved on-resin overnight with GST-TEV protease, and the GST-TEV
and  cleaved  GST  tag  were  separated  from Cdk2-Spy1  complex with  glutathione
Sepharose.  Trace  amounts  of  cleaved  MBP  were  separated  from  Cdk2-Spy1
complex with amylose resin. To express Cdk2 phosphorylated on T160, GST-tagged
Cdk2 was coexpressed with yeast CAK from the pRSFduet vector in BL21  E. coli.
Cdk2-CycA and Cdk2-Spy1 complexes for kinase assays were prepared without the
cleavage of  the tags.  Tagged proteins were eluted from amylose resin with 1%
maltose, mixed with glycerol (final 10% glycerol by volume), aliquoted, and flash-
frozen in liquid nitrogen. Full-length human p27, the p27 kinase inhibitory domain
(p27KID, residues 22-93), and the FoxM1 and Rb proteins constructs were expressed
as  GST-fusion proteins in  E.  coli and purified using affinity  and anion exchange
chromatography.
Crystallization and structure determination
The  Cdk2-Spy1  (S/R  box)  complex  was  subjected  to  limited  proteolysis  with
0.01% trypsin for 30 min on ice. The trypsinized complex appeared on a denaturing
gel as a stable band with a small decrease in mass. After trypsinizing, Cdk2-Spy1
complex was  prepared  for  crystallization  by  final  purification  using  a  HiLoad
Superdex  200  (GE  Healthcare)  column  equilibrated  in  a  buffer  containing  12.5
mM HEPES pH 7.5, 150 mM NaCl, and 1 mM TCEP. The final concentration of protein
complex used for purification was 5 mg/mL. Proteins were crystallized by sitting-
drop vapor diffusion at 20 °C. Two different crystal forms were grown for 4 weeks.
An initial dataset was collected from a crystal grown in 1M lithium chloride, 12%
PEG 6000, and 0.1M MES pH 6.2, harvested and flash frozen in the same solution
with 20% PEG 200.  A second data set  was collected from a crystal  grown in a
solution containing 900 mM potassium sodium tartrate, 200 mM lithium sulfate, and
0.1  M CHES pH 9.3.  The  crystals  were  harvested  and flash  frozen  in  the  same
solution with 15% glycerol.
The Cdk2-Spy1-p27 ternary complex was assembled from the S/R box of human
Spy1A,  full  length  Cdk2,  and  full  length  p27.  Purified  p27  was  mixed  in  slight
stoichiometric  excess  with  Cdk2-Spy1  following  purification  of  the  dimer  over
Superdex 200. The ternary complex was then purified to 11.5 mg/mL. Crystals of
the ternary complex were grown by sitting drop vapor diffusion at 20C in 5% PEG
6000 and 0.1M MES pH5, harvested and flash frozen in 20% PEG 200. 
Data were collected at λ = 1.0332Å, 100 K on Beamline 23-ID-D at the Advanced
Photon Source, Argonne National Laboratory. Diffraction spots were integrated with
Mosflm  (Leslie,  2006) and scaled  with  SCALE-IT  (Howell  &  Smith,  1992).  Phases
were solved by molecular replacement with PHASER  (Mccoy, Grosse-Kunstleve et
al., 2007). CDK2 (PDB: 1QMZ) was used as a search model to solve the first data set
(P3121 crystal form, grown in PEG 6000). The initial model was rebuilt with Coot
(Emsley  &  Cowtan,  2004),  and  Speedy  was  added  to  the  unmodeled  electron
density. The resulting model was refined with Phenix (Adams, Afonine et al., 2010).
Several  rounds  of  position  refinement  with  simulated  annealing  and  individual
temperature-factor  refinement  with  default  restraints  were  applied.  The  second
data set (P3121 crystal form, grown in sodium tartrate) and the data set for the
ternary complex crystal  were collected and processed as above. Both structures
were solved by molecular  replacement using the structure from the first  binary
complex crystal as a search model. The final refined models were deposited in the
Protein Data Bank under Accession Codes 5UQ1, 5UQ2, and 5UQ3.
Kinase assays
Kinase reactions were performed in a volume of 100 L in a buffer containing 25
mM Hepes, 200 mM NaCl, 10 mM MgCl2, 1 mM DTT, 200 M ATP, and 100Ci of 32P-
gamma-ATP  (pH  7.0).  Substrate  was  diluted  into  the  reaction  buffer  at  the
appropriate concentration, and the reaction was initiated through addition of kinase.
Reactions were quenched after 10 minutes though addition of SDS-PAGE loading
buffer. Independent time course experiments confirmed that phosphate addition is
still  linear  with  time  beyond  30  minutes  using  our  experimental  conditions.
Electrospray  mass  spectrometry  confirmed  that  under  conditions  that  drive  the
kinase reactions to completion–near stoichiometric concentrations of kinase–5 and 7
phosphates  are  incorporated  into  FoxM1  and  RbC  respectively.  Such  a
stoichiometric reaction was performed with each 32P-assay, and the band from the
quantitatively  phosphorylated  substrate  was  used  as  a  standard  to  calculate
phosphate concentration  from band intensity.  This  phosphate  concentration  was
then used to determine initial rate of phosphate incorporation. SDS-PAGE gels were
imaged with a Typhoon scanner and bands quantified using the ImageJ software
package. For each assay, three replicates were performed. The kinetic parameters
(KM, Vmax, Ki) were determined for each individual replicate, and the reported values
are averages of the three replicates with standard deviations reported as errors.
The data points and error bars shown in the figure graphs are the averages and
standard deviations respectively of initial rates at each concentration point across
the three replicates.
Isothermal titration calorimetry
ITC was performed using the MicroCal VP-ITC calorimeter.  Cdk2-Spy1 S/R box
and p27 KID were buffer exchange over Superdex 200 into 20 mM Hepes (pH 7.5),
200 mM NaCl, and 5 mM DTT. p27 at concentrations between 100 and 270 μM was
titrated  into  Cdk2-Spy1 S/R box  at  concentrations  between 14 and 25 μM. Data
were analyzed with the Origin calorimetry software package assuming a one-site
binding model. Experiments were performed in triplicate, and the reported error is
the standard deviation of each set of measurements.
Cell culture assays
The  pCS3  and  Myc-Spy1-pCS3  vectors  were  generated  as  previously
described(Porter et al., 2002). Site-directed mutagenesis was performed to create
the Myc-Spy1-D97N/E135Q-pCS3 vector. HEK 293 and NIH 3T3 cells were cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal bovine serum and
1% penicillin/streptomycin at 37°C and 5% CO2. Transient transfection of HEK-293
cells was conducted using 25ug of polyethylenimine (PEI) and 10ug of DNA. DNA
and PEI were incubated for 10 minutes at room temperature in base medium before
added to the plate. The transfection reagent was removed after 16 to 18 hours.
Transient transfection of NIH 3T3 cells required 10ug of DNA and 30ug of PEI to
500uL of 1xPBS, vortexed briefly and allowed to incubate for 10 minutes at room
temperature. Just prior to addition of the DNA PEI complex, the media on the plate
was changed to two-thirds serum free media and one-third 1xPBS. The DNA PEI
complex was added to the cells and incubated at 37°C 5% CO2 for 4 hours. After 4
hours, the media was changed to full growth media. 
Transfection was monitored using quantitative real-time (qRT)-PCR. RNA was
isolated  using  Qiagen  RNeasy  Kit  following  manufacturer’s  instructions.  Equal
amounts  of  cDNA  was  synthesized  using  qScript  cDNA  SuperMix  following
manufacturer’s instructions. qRT-PCR was performed using SYBR Green Detection
(Applied Biosystems), and was analyzed using the Viia7 Real Time PCR System (Life
Technologies) and software. 
Cell proliferation assays were conducted by seeding cells in a 24 well plate at a
density  of  15,000  cells  per  well.  Trypan  blue  exclusion  analysis  was  used  to
determine cell viability at 5 days post seeding and assess rates of proliferation. 
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Figure Captions
Figure 1. Spy1 binding induces an active Cdk2 conformation. (A)  Overall
structure of the Cdk2-Spy1 (S/R box) complex. (B) Comparison of kinase domain
structures  between  Cdk2  alone  and  Cdk2  in  complex  with  CycA  or  Spy1.  The
conformation of the PSTAIRE helix (E51 pointed toward the active site) and T-loop
(extended  away  from the  active  site)  in  the  Spy1  complex  are  similar  to  their
conformations in the active CycA complex. (C) Comparison of CycA and Spy1 bound
to  Cdk2  generated  by  alignment  of  the  kinase  domain  in  the  two  complex
structures.  Spy  has  a  single  Cyclin-box  fold,  and  the  helices  that  contact  the
PSTAIRE helix have similar position and orientation to the analogous helices in CycA.
(D) Sequence alignment of Spy1 homologs within the S/R box domain. Secondary
structure  from  the  Cdk2-Spy1A  structure  are  shown,  with  dashed  lines
corresponding to sequences for which there was no observable electron density.
Residues in Spy1 that contact the Cdk2 PSTAIRE helix (red squares) and T-loop (red
circles) are indicated.
Figure 2. Spy1 interactions with the Cdk2 PSTAIRE helix. (A) Close-up view of
the Spy1-PSTAIRE interface. (B) Comparison of PSTAIRE helix interactions between
Spy1 and CycA.
Figure 3. Cdk2-Spy1 activity is insensitive to Cdk2 T-loop phosphorylation.
(A)  Comparison  of  T-loop conformations  in  the indicated  Cdk2 complexes.  Spy1
induces  a  T-loop  structure  that  is  more  similar  to  the  active  conformation  in
phosphorylated Cdk2. The position of the T-loop T160 is shown in each structure.
(B)  Radiolabeled  phosphate  incorporation  into  increasing  amounts  of  FoxM1
substrate by the indicated kinase complex in a 10 minute reaction with 32P-ATP. The
lanes correspond to 1, 2, 4, 8, 12, and 20 mM FoxM1. The assay was performed with
Cdk2-CycA and Cdk2-Spy1 S/R box. (C) Initial kinase reaction rates determined from
quantification of bands in experiments as in (B). Reported values are averages from
three different experiments with the standard deviations shown as error bars. The
kinetic parameters (with standard deviations reported as errors) averaged over the
three replicates are shown in the table.
Figure 4. Spy1 coordinates the Cdk2 T-loop using several conserved acidic
sidechains.  (A)  Close-up  view of  the  Spy1  interface  with  the  Cdk2  T-loop.  (B)
Mutation of D97 and E135 in full length Spy1 (Spy1 DE) abrogates kinase activity as
observed in the same assay described in Fig. 3B. (C) HEK 293 and NIH 3T3 cells
were  transiently  transfected  with  empty  vector  control  (vector),  Spy1-wildtype
(Spy1) or Spy1-DE (Spy1 DE) and RT-qPCR was used to confirm transfection and
monitor expression levels (bottom graphs). Trypan blue exclusion analysis was used
to assess proliferation after 5 days (top graphs). Error bars represent standard error
(n=3); Student’s T-Test; *p<0.05, **p<0.01
Figure 5. Spy1 lacks the binding-cleft for Cdk inhibitors and substrates. (A)
Comparison of CycA and Spy1 generated by alignment of the Cdk2 kinase domains
in the Cdk2-Spy1 and Cdk2-CycA-p27 structures. Spy1 lacks the MRAIL binding cleft,
present in CycA, into which p27 docks. (B) p27 potently inhibits Cdk2-CycA but not
Cdk2-Spy1.  Kinase assay  as in Fig.  3 with 4  M FoxM1 substrate  and using full
length Spy1. Concentrations of p27 in each reaction are 0, 75, 150, 300, 600, 1200,
and 2400 nM from left to right. (C) Crystal structure of the p27KID-Cdk2-CycA ternary
complex.
Figure  6.  Cdk2-Spy1  is  less  sensitive  to  the  presence  of  a  substrate-
docking site than Cdk2-CycA. Kinase assay as performed in Fig. 3 but using full
length  Spy1  and  the  Rb  C-terminal  domain  (RbC,  7  consensus  Cdk  sites)  as  a
substrate. F877A contains a mutation in the RxLF sequence that docks to the MRAIL
site in CycA.
Figure EV1. Sequence comparison of Spy1 with other Cyclin-like proteins.
The secondary structure elements in the Spy1 Cyclin box fold (CBF) and Cyclin A
CBF are indicated. Overall pairwise % sequence identity between each sequence
and Spy1A is shown in the table. Sequences were aligned using Clustal W.
Figure  EV2.  Cdk2-Spy1  kinase  reactions  using  the  retinoblastoma  (Rb)
protein C-terminal domain. Kinase assays as described in Fig. 3 except using
Rb771-875, which contains 7 Cdk consensus sites, as substrate.
Figure EV3. Isothermal titration calorimetry assay of p27 kinase inhibitory domain
(KID) binding to Cdk2-Spy1 (S/R box).
Table EV1. X-ray diffraction data collection and refinement statistics
Cdk2-Spy1 Cdk2-Spy1 p27-Cdk2-Spy1
Data collection
Space group P3121 P41212 P3121
Unit cell dimensions
(a,b,c) (Å), (α, β, γ)
(º)
75.36, 75.36,
325.79
90, 90, 120
120.91, 120.91,
77.11
90, 90, 90
124.65, 124.65,
88.49
90, 90, 120
Resolution Range
(Å)
46.1-3.2 (3.42-
3.2)
85.5-2.7 (2.83-
2.70)
68.44-3.60 (3.94-
3.60)
Wavelength (Å) 1.02 1.02 1.02
Total observations* 109880 (8971) 129383 (16892) 66196
Unique reflections      17634(2668) 16255(2107) 9501 (2220)
Completeness (%)                  94.7 (81.3) 99.9 (100) 100 (100)
Rmerge 17.0 (80.9) 11.7 (128.1) 19.0 (94.4)
<I/σ> 7.9 (2.3) 12.6 (2.0) 6.5 (2.0)
CC(1/2) 0.98 (0.62) 0.99 (0.68) 0.99 (0.68)
Redundancy 6.2 (3.4) 8.0 (8.0) 7.0 (7.0)
Refinement
Rwork %/ Rfree % 20.5/26.1 21.2/27.5 24.3/32.4
Number of atoms 6916 3503 3680
Protein 6916 3480 3680
Water 0 23 0
B-factor (Average
(Å)2) 67 65 119
RMSD Bond length
(Å) 0.006 0.003 0.004
 RMSD Bond angle 2.05 0.76 1.02
Ramachandran
outliers (%) 1.2 0.2 0.2
